Brailly H - Search Results

1

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH. Tartour E, et al. Among authors: brailly h. Br J Cancer. 1994 May;69(5):911-3. doi: 10.1038/bjc.1994.175. Br J Cancer. 1994. PMID: 8180022 Free PMC article.

2

Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.

Montero-Julian FA, Brailly H, Sautès C, Joyeux I, Dorval T, Mosseri V, Yasukawa K, Wijdenes J, Adler A, Gorin I, Fridman WH, Tartour E. Montero-Julian FA, et al. Among authors: brailly h. Clin Cancer Res. 1997 Aug;3(8):1443-51. Clin Cancer Res. 1997. PMID: 9815830

3

Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.

Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B. Lu ZY, et al. Among authors: brailly h. Cytokine. 1993 Nov;5(6):578-82. doi: 10.1016/s1043-4666(05)80007-9. Cytokine. 1993. PMID: 8186369

4

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.

Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Lu ZY, et al. Among authors: brailly h. Blood. 1995 Oct 15;86(8):3123-31. Blood. 1995. PMID: 7579407 Free article. Clinical Trial.

5

Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.

Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B. Gaillard JP, et al. Among authors: brailly h. Eur J Immunol. 1993 Apr;23(4):820-4. doi: 10.1002/eji.1830230408. Eur J Immunol. 1993. PMID: 8458373

6

IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapy.

Han D, Pottin-Clemenceau C, Imro MA, Scudeletti M, Doucet C, Puppo F, Brouty-Boye D, Vedrenne J, Sahraoui Y, Brailly H, Poggi A, Jasmin C, Azzarone B, Indiveri F. Han D, et al. Among authors: brailly h. Oncogene. 1996 Mar 7;12(5):1015-23. Oncogene. 1996. PMID: 8649792

7

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. Lu ZY, et al. Among authors: brailly h. Eur J Immunol. 1992 Nov;22(11):2819-24. doi: 10.1002/eji.1830221110. Eur J Immunol. 1992. PMID: 1425909

8

Targeting of interleukin-2 to the periplasm of Escherichia coli.

Halfmann G, Brailly H, Bernadac A, Montero-Julian FA, Lazdunski C, Baty D. Halfmann G, et al. Among authors: brailly h. J Gen Microbiol. 1993 Oct;139(10):2465-73. doi: 10.1099/00221287-139-10-2465. J Gen Microbiol. 1993. PMID: 8254317

9

Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies.

Montero-Julian FA, Klein B, Gautherot E, Brailly H. Montero-Julian FA, et al. Among authors: brailly h. Blood. 1995 Feb 15;85(4):917-24. Blood. 1995. PMID: 7849313 Free article.

10

Total interleukin-6 in plasma measured by immunoassay.

Brailly H, Montero-Julian FA, Zuber CE, Flavetta S, Grassi J, Houssiau F, vanSnick J. Brailly H, et al. Clin Chem. 1994 Jan;40(1):116-23. Clin Chem. 1994. PMID: 8287518

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters